(Q50641615)

17 March 2018

title

Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension. (English)

1 reference

17 March 2018

author name string

Petros AJ

series ordinal

1

1 reference

17 March 2018

Turner SC

series ordinal

2

1 reference

17 March 2018

Nunn AJ

series ordinal

3

1 reference

17 March 2018

publication date

1 July 1995

1 reference

17 March 2018

Journal of Pharmacy Technology

published in

1 reference

17 March 2018

volume

11

1 reference

17 March 2018

issue

4

1 reference

17 March 2018

page(s)

163-166

1 reference

17 March 2018

Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F875512259501100409

Inhaled nitric oxide in persistent pulmonary hypertension of the newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F875512259501100409

Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F875512259501100409

Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F875512259501100409

Inhaled nitric oxide in congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F875512259501100409

10.1177/875512259501100409

21 January 2018

Identifiers

DOI

1 reference

17 March 2018

1 reference

17 March 2018